Randomized, Double-Blind Comparison of Once-Weekly Dalbavancin versus Twice-Daily Linezolid Therapy for the Treatment of Complicated Skin and Skin Structure Infections
Clinical Infectious Diseases2005Vol. 41(10), pp. 1407–1415
Citations Over TimeTop 1% of 2005 papers
L. E. Jauregui, S. Babazadeh, Elyse Seltzer, L. Goldberg, Dainis Krieviņš, Mitchell J. Frederick, David Krause, I. Satilovs, Žilvinas Endzinas, J. Breaux, W. O'Riordan
Abstract
Two doses of dalbavancin (1000 mg given on day 1 followed by 500 mg given on day 8) were as well tolerated and as effective as linezolid given twice daily for 14 days for the treatment of patients with complicated SSSI, including those infected with MRSA.
Related Papers
- → In vitro activity of daptomycin combined with dalbavancin and linezolid, and dalbavancin with linezolid against MRSA strains(2016)22 cited
- → Single-Dose Treatment With Dalbavancin for Acute Bacterial Skin and Skin Structure Infection(2015)4 cited
- [In vitro activity of linezolid and dalbavancin against vancomycin-resistant enterococci].(2012)
- → Dalbavancin, Oritavancin and Tedizolid are Safe and Effective for Skin Infection Treatment(2014)
- Linezolid (LZD) and Vancomycin (VAN) in the Treatment of Complicated Skin and Skin Structure Infections (cSSSI) Proven to Be Due to Methicillin-Resistant Staphylococcus aureus (MRSA) Among Diabetics(2009)